Dorsey & Whitney Trust CO LLC Lowers Stock Holdings in Stryker Corporation $SYK

Key Points

• Dorsey & Whitney Trust CO LLC has reduced its stake in Stryker Corporation by 16.0%, now owning 4,663 shares valued at approximately $1,736,000.
• Several institutional investors have recently increased or established new positions in Stryker, with hedge funds owning 77.09% of the company's stock.
• Stryker's recent quarterly earnings surpassed estimates, reporting $3.13 EPS and revenue of $6.02 billion, reflecting an 11.1% year-over-year increase.

Dorsey & Whitney Trust CO LLC cut its position in Stryker Corporation (NYSE:SYK - Free Report) by 16.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,663 shares of the medical technology company's stock after selling 891 shares during the quarter. Dorsey & Whitney Trust CO LLC's holdings in Stryker were worth $1,736,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Capital A Wealth Management LLC purchased a new position in shares of Stryker in the fourth quarter valued at approximately $26,000. Goodman Advisory Group LLC acquired a new stake in Stryker during the 1st quarter worth approximately $32,000. City Holding Co. boosted its position in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker in the first quarter worth $40,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Stryker during the fourth quarter worth $42,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Needham & Company LLC lifted their target price on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a report on Friday, August 1st. Sanford C. Bernstein set a $450.00 price target on Stryker in a research report on Monday, May 5th. JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Wells Fargo & Company upped their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Finally, Citigroup reiterated a "buy" rating and issued a $455.00 price target (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $430.10.

Stryker Price Performance

SYK stock opened at $392.0050 on Thursday. The business has a 50 day moving average price of $387.09 and a 200 day moving average price of $379.54. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market cap of $149.87 billion, a price-to-earnings ratio of 51.92, a PEG ratio of 2.83 and a beta of 0.91. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm's revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's payout ratio is 44.50%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.